Early Parkinson Disease
Key Points
Key Points
- The treatment options for the alleviation of motor symptoms in the early stages of Parkinson disease (PD) are based on the enhancement of dopaminergic tone with levodopa, monoamine oxidase inhibitors, dopamine agonists (DAs), or a combination thereof.
- The choice of initial treatment is influenced by the potential for neuropsychiatric adverse effects associated with DAs and dyskinesia and motor fluctuations associated with levodopa.
- The treatment options for the alleviation of motor symptoms in the early stages of Parkinson disease (PD) are based on the enhancement of dopaminergic tone with levodopa, monoamine oxidase inhibitors, dopamine agonists (DAs), or a combination thereof.
- The choice of initial treatment is influenced by the potential for neuropsychiatric adverse effects associated with DAs and dyskinesia and motor fluctuations associated with levodopa.
Treatment
...atment...
...pa vs. DAs vs. MAO-B inhibitors...
...ld counsel patients with early PD on th...
...s with early PD who seek treatment for motor sy...
...may prescribe DAs as the initial dopami...
...linicians should not prescribe DAs to patients wit...
...ibing levodopa...
...should initially prescribe immediate-release l...
...patients with early PD, clinicians should p...
...should routinely monitor patients...
...hould counsel patients taking levodopa tha...
...nicians should counsel patients that in later dise...
...escribing DAs
...nicians should inform the patient and...
...hould screen patients for cognitive impairm...
...uld screen patients for the presenc...
...nicians should involve caregivers in assessmen...
...inicians may screen patients for the presence o...
...ould integrate patient preferences concernin...
Clinicians should prescribe the lowest dose...
Tapering and Discontinu...
...ld recommend tapering or discontinuation of D...
...be discontinued due to adverse effects, clinic...
...ibing MAO-B inhibitors...
...ns should counsel patients with early PD on...
...cians may prescribe MAO-B inhibitors...
...ations for Parkinson DiseaseHaving tr...